Literature DB >> 24491580

Type I interferons promote severe disease in a mouse model of lethal ehrlichiosis.

Yubin Zhang1, Vinh Thai, Amanda McCabe, Maura Jones, Katherine C MacNamara.   

Abstract

Human monocytic ehrlichiosis (HME) is caused by a tick-borne obligate intracellular pathogen of the order Rickettsiales. HME disease can range from mild to a fatal, toxic shock-like syndrome, yet the mechanisms regulating pathogenesis are not well understood. We define a central role for type I interferons (alpha interferon [IFN-α] and IFN-β) in severe disease in a mouse model of fatal ehrlichiosis caused by Ixodes ovatus Ehrlichia (IOE). IFN-α and IFN-β were induced by IOE infection but not in response to a less virulent strain, Ehrlichia muris. The major sources of type I IFNs during IOE infection were plasmacytoid dendritic cells and monocytes. Mice lacking the receptor for type I IFNs (Ifnar deficient) or neutralization of IFN-α and IFN-β resulted in a reduced bacterial burden. Ifnar-deficient mice exhibited significantly increased survival after IOE infection, relative to that of wild-type (WT) mice, that correlated with increased type II IFN (IFN-γ) production. Pathogen-specific antibody responses were also elevated in Ifnar-deficient mice, and this required IFN-γ. Remarkably, increased IFN-γ and IgM were not essential for protection in the absence of type I IFN signaling. The direct effect of type I IFNs on hematopoietic and nonhematopoietic cells was evaluated in bone marrow chimeric mice. We observed that chimeric mice containing Ifnar-deficient hematopoietic cells succumbed to infection early, whereas Ifnar-deficient mice containing WT hematopoietic cells exhibited increased survival, despite having a higher bacterial burden. These data demonstrate that IFN-α receptor signaling in nonhematopoietic cells is important for pathogenesis. Thus, type I IFNs are induced during a rickettsial infection in vivo and promote severe disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24491580      PMCID: PMC3993392          DOI: 10.1128/IAI.01564-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  68 in total

1.  Animal model of fatal human monocytotropic ehrlichiosis.

Authors:  E A Sotomayor; V L Popov; H M Feng; D H Walker; J P Olano
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

2.  New Ehrlichia species closely related to Ehrlichia chaffeensis isolated from Ixodes ovatus ticks in Japan.

Authors:  S Shibata; M Kawahara; Y Rikihisa; H Fujita; Y Watanabe; C Suto; T Ito
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

3.  The Type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis.

Authors:  Sarah A Stanley; James E Johndrow; Paolo Manzanillo; Jeffery S Cox
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

Review 4.  IFN-α in the treatment of melanoma.

Authors:  Ahmad A Tarhini; Helen Gogas; John M Kirkwood
Journal:  J Immunol       Date:  2012-10-15       Impact factor: 5.422

5.  Visualization of IFNbeta production by plasmacytoid versus conventional dendritic cells under specific stimulation conditions in vivo.

Authors:  Stefanie Scheu; Philipp Dresing; Richard M Locksley
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

6.  Diminished hematopoietic activity associated with alterations in innate and adaptive immunity in a mouse model of human monocytic ehrlichiosis.

Authors:  Katherine C MacNamara; Rachael Racine; Madhumouli Chatterjee; Dori Borjesson; Gary M Winslow
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

7.  Phase I study of recombinant tumor necrosis factor in cancer patients.

Authors:  M Blick; S A Sherwin; M Rosenblum; J Gutterman
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

8.  CD11c expression identifies a population of extrafollicular antigen-specific splenic plasmablasts responsible for CD4 T-independent antibody responses during intracellular bacterial infection.

Authors:  Rachael Racine; Madhumouli Chatterjee; Gary M Winslow
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

9.  Imbalance of angiopoietin-1 and angiopoetin-2 in severe dengue and relationship with thrombocytopenia, endothelial activation, and vascular stability.

Authors:  Meta Michels; André J A M van der Ven; Kis Djamiatun; Rob Fijnheer; Philip G de Groot; Arjan W Griffioen; Silvie Sebastian; Sultana M H Faradz; Quirijn de Mast
Journal:  Am J Trop Med Hyg       Date:  2012-09-04       Impact factor: 2.345

10.  An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.

Authors:  Matthew P R Berry; Christine M Graham; Finlay W McNab; Zhaohui Xu; Susannah A A Bloch; Tolu Oni; Katalin A Wilkinson; Romain Banchereau; Jason Skinner; Robert J Wilkinson; Charles Quinn; Derek Blankenship; Ranju Dhawan; John J Cush; Asuncion Mejias; Octavio Ramilo; Onn M Kon; Virginia Pascual; Jacques Banchereau; Damien Chaussabel; Anne O'Garra
Journal:  Nature       Date:  2010-08-19       Impact factor: 49.962

View more
  15 in total

1.  Macrophage-Lineage Cells Negatively Regulate the Hematopoietic Stem Cell Pool in Response to Interferon Gamma at Steady State and During Infection.

Authors:  Amanda McCabe; Yubin Zhang; Vinh Thai; Maura Jones; Michael B Jordan; Katherine C MacNamara
Journal:  Stem Cells       Date:  2015-05-22       Impact factor: 6.277

2.  Influence of Genetic Background on Hematologic and Histopathologic Alterations during Acute Granulocytic Anaplasmosis in 129/SvEv and C57BL/6J Mice Lacking Type I and Type II Interferon Signaling.

Authors:  Jennifer L Johns; Marielle L Discipulo; Amanda L Koehne; Kaitlin A Moorhead; Claude M Nagamine
Journal:  Comp Med       Date:  2017-03-01       Impact factor: 0.982

Review 3.  The application of oncolytic viruses in cancer therapy.

Authors:  Yang Gao; Yan Wu; Tian Huan; Xiaoyan Wang; Jun Xu; Qinggang Xu; Feng Yu; Haifeng Shi
Journal:  Biotechnol Lett       Date:  2021-08-26       Impact factor: 2.461

4.  Review: Protective Immunity and Immunopathology of Ehrlichiosis.

Authors:  Nahed Ismail; Aditya Sharma; Lynn Soong; David H Walker
Journal:  Zoonoses (Burlingt)       Date:  2022-07-05

5.  Type I interferon contributes to noncanonical inflammasome activation, mediates immunopathology, and impairs protective immunity during fatal infection with lipopolysaccharide-negative ehrlichiae.

Authors:  Qin Yang; Heather L Stevenson; Melanie J Scott; Nahed Ismail
Journal:  Am J Pathol       Date:  2014-12-04       Impact factor: 4.307

6.  Type I Interferon Supports Inducible Nitric Oxide Synthase in Murine Hepatoma Cells and Hepatocytes and during Experimental Acetaminophen-Induced Liver Damage.

Authors:  Malte Bachmann; Zoe Waibler; Thomas Pleli; Josef Pfeilschifter; Heiko Mühl
Journal:  Front Immunol       Date:  2017-07-31       Impact factor: 7.561

7.  MyD88-dependent inflammasome activation and autophagy inhibition contributes to Ehrlichia-induced liver injury and toxic shock.

Authors:  Muhamuda Kader; Mounia Alaoui-El-Azher; Jennie Vorhauer; Bhushan B Kode; Jakob Z Wells; Donna Stolz; George Michalopoulos; Alan Wells; Melanie Scott; Nahed Ismail
Journal:  PLoS Pathog       Date:  2017-10-19       Impact factor: 6.823

Review 8.  Type I interferons in bacterial infections: taming of myeloid cells and possible implications for autoimmunity.

Authors:  Emily M Eshleman; Laurel L Lenz
Journal:  Front Immunol       Date:  2014-09-11       Impact factor: 7.561

Review 9.  Unraveling the convoluted biological roles of type I interferons in infection and immunity: a way forward for therapeutics and vaccine design.

Authors:  Danushka Kumara Wijesundara; Yang Xi; Charani Ranasinghe
Journal:  Front Immunol       Date:  2014-08-29       Impact factor: 7.561

Review 10.  Hematopoietic Stem Cell Regulation by Type I and II Interferons in the Pathogenesis of Acquired Aplastic Anemia.

Authors:  Julianne N P Smith; Vikramjit S Kanwar; Katherine C MacNamara
Journal:  Front Immunol       Date:  2016-08-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.